Aanastra

Aanastra is pioneering a novel approach to RNA therapeutics with its proprietary PEP-NP™ peptide-based delivery platform, designed to solve the critical industry challenge of targeted, systemic, and repeatable RNA delivery beyond the liver. The company's pipeline is focused on three high-impact, platform-enabled strategies: restoring tumor suppressor function (TSG-RESCUE™), generating CAR-T cells in vivo (PEP-CAR™), and editing/deleting oncogenes (ONCOEDIT™). As a private, pre-revenue company, Aanastra is positioned to address large unmet needs in oncology and autoimmune diseases, though it faces significant technical and competitive risks inherent to the novel drug delivery and gene modulation space.

Proprietary peptide-based nanoparticle (PEP-NP™) technology designed for precise systemic in vivo targeting and efficient cellular release of RNA payloads, aiming to overcome limitations of viral vectors and lipid nanoparticles.

Aanastra competes with numerous entities developing next-generation RNA delivery systems, including companies advancing engineered LNPs, viral vectors, and other non-viral platforms. It also faces future competition from other modalities targeting the same genetic drivers (e.g., small molecule KRAS inhibitors, other gene editing approaches).